{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:14:44Z","timestamp":1790082884206,"version":"4.0.1"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is crucial for manufacturing CARs. Ideally, a target surface molecule should be restricted to tumor cells and minimally expressed or absent on normal tissues. Different CD19-targeted CAR-T cell therapies have been approved for the treatment of B-cell lymphoid malignancies that are refractory to other therapies, including indolent and aggressive B-cell non-Hodgkin lymphomas (NHL) and B-cell acute lymphoblastic leukemia (BALL). Despite impressive results, many patients with aggressive and refractory B-cell malignancies do not respond to or relapse after CD19 CAR-T cell therapies. Thus, several additional strategies are currently being evaluated to overcome these limitations. This review discusses studies on other promising CAR-T cell targets, including CD20, CD22, BAFF-R, ROR1, CD70, BCR complex, kappa\/lambda light chains, multitargeted CAR-T cells, and combinations of CAR-T cell therapy with different drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1026","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T05:28:07Z","timestamp":1671686887000},"page":"81-93","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["CAR-T cell Therapies for B-cell Lymphoid Malignancies"],"prefix":"10.4103","volume":"15","author":[{"given":"Yenny M.","family":"Vanegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha E.","family":"Gadd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20241211","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"R2-3-20241211","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody- modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"R4-3-20241211","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CART therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R5-3-20241211","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol Rev"},{"key":"R6-3-20241211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/gene.2010.22","article-title":"B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele","volume":"11","author":"Artac","year":"2010","journal-title":"Gene Immun"},{"key":"R7-3-20241211","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1385\/IR:31:2:119","article-title":"CD19 function in central and peripheral B-cell development","volume":"31","author":"Del Nagro","year":"2005","journal-title":"Immunol Res"},{"key":"R8-3-20241211","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","article-title":"A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice","volume":"189","author":"Poe","year":"2012","journal-title":"J Immunol"},{"key":"R11-3-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-3-20241211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R13-3-20241211","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"R14-3-20241211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-3-20241211","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"R17-3-20241211","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-3-20241211","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R19-3-20241211","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"R20-3-20241211","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"R21-3-20241211","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenle- cleucel in patients with relapsed or refractory aggressive B- cell lymphomas (JULIET): a multicentre, open-label, singlearm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"R22-3-20241211","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R23-3-20241211","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expet Opin Biol Ther"},{"key":"R24-3-20241211","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"R25-3-20241211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"key":"R26-3-20241211","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"R27-3-20241211","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20- directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"R28-3-20241211","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B- cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Targeted Ther"},{"key":"R29-3-20241211","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/2326-6066.CIR-15-0276","article-title":"Preserved activity of CD20-specific chimeric antigen receptor-expressing T cells in the presence of rituximab","volume":"4","author":"Rufener","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R30-3-20241211","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"R31-3-20241211","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.immunol.15.1.481","article-title":"CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling","volume":"15","author":"Tedder","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"R32-3-20241211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/intimm\/3.7.623","article-title":"CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion","volume":"3","author":"Schwartz-Albiez","year":"1991","journal-title":"Int Immunol"},{"key":"R33-3-20241211","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3083.2002.01063.x","article-title":"Expression and function of CD22, a B-cell restricted molecule","volume":"55","author":"Moyron-Quiroz","year":"2002","journal-title":"Scand J Immunol"},{"key":"R34-3-20241211","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1309\/KPXNVR7X4AMENBBE","article-title":"Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lympho- proliferative disorders from admixed benign B cells in four- color multiparameter flow cytometry","volume":"123","author":"Huang","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R35-3-20241211","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-11-1374","article-title":"Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates","volume":"71","author":"FitzGerald","year":"2011","journal-title":"Cancer Res"},{"key":"R36-3-20241211","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"R37-3-20241211","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19- targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"R38-3-20241211","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T- cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"R39-3-20241211","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"R40-3-20241211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/2643-3230.BCD-21-0087","article-title":"Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies","volume":"3","author":"Zheng","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"R41-3-20241211","doi-asserted-by":"crossref","first-page":"101277","DOI":"10.1016\/j.beha.2021.101277","article-title":"New targets for CAR T therapy in hematologic malignancies. Epub 20210609","volume":"34","author":"Savani","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"R42-3-20241211","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1084\/jem.20100857","article-title":"A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling","volume":"207","author":"Hildebrand","year":"2010","journal-title":"J Exp Med"},{"key":"R43-3-20241211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3960\/jslrt.50.121","article-title":"BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas","volume":"50","author":"Takahata","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"R45-3-20241211","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","article-title":"Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions","volume":"69","author":"Dong","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R46-3-20241211","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12935-021-01923-x","article-title":"TriBAFF- CAR-T cells eliminate B-cell malignancies with BAFFR- expression and CD19 antigen loss","volume":"21","author":"Li","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R47-3-20241211","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"R49-3-20241211","doi-asserted-by":"crossref","first-page":"e78339","DOI":"10.1371\/journal.pone.0078339","article-title":"The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PLoS One"},{"key":"R50-3-20241211","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R51-3-20241211","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R52-3-20241211","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R53-3-20241211","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.154.6.2612","article-title":"Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation","volume":"154","author":"Hintzen","year":"1995","journal-title":"J Immunol"},{"key":"R54-3-20241211","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cac2.12201","article-title":"CD70- targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Epub 20210727","volume":"41","author":"Deng","year":"2021","journal-title":"Cancer Commun"},{"key":"R55-3-20241211","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"R56-3-20241211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur J Haematol"},{"key":"R57-3-20241211","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19","volume":"25","author":"Ormh\u2298j","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R58-3-20241211","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10428194.2021.1980214","article-title":"Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R59-3-20241211","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"R60-3-20241211","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells","volume":"108","author":"Vera","year":"2006","journal-title":"Blood"},{"key":"R61-3-20241211","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"R62-3-20241211","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"R63-3-20241211","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"R64-3-20241211","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R65-3-20241211","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"R66-3-20241211","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"R67-3-20241211","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"R68-3-20241211","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"R69-3-20241211","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R70-3-20241211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R71-3-20241211","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"R72-3-20241211","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R73-3-20241211","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","article-title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica"},{"key":"R74-3-20241211","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"R75-3-20241211","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R77-3-20241211","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"R78-3-20241211","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"R79-3-20241211","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell- intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"R80-3-20241211","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T- cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"R81-3-20241211","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood-2018-99-116745","article-title":"Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed\/refractory aggressive B-cell non-hodgkin lymphoma","volume":"132","author":"Hirayama","year":"2018","journal-title":"Blood"},{"key":"R82-3-20241211","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19- directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"R83-3-20241211","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B- cell non-hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"R85-3-20241211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:50Z","timestamp":1787758010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1026"}},"subtitle":["Identifying Targets Beyond CD19"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1026","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}